A Randomized Study of Head and Neck Radiotherapy With or Without Customized 3D Printed Oral Stents
Summary
This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients' teeth and gums during radiation therapy. A customized, 3D-printed oral stent may help to reduce mouth blisters and/or sores that may develop in patients while receiving head and neck radiation therapy.
Detailed description
PRIMARY OBJECTIVE: I. To evaluate the acute mucositis rates in non-target mucosa of patients who receive head and neck radiation with or without a customized 3D printed oral stent. SECONDARY OBJECTIVES: I. To record patient reported outcomes during radiotherapy. II. To evaluate patient narcotic use during radiotherapy. III. To evaluate the imaging and dosimetric differences in head and neck radiotherapy with and without a customized 3D printed oral stent. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients wear 3D printed oral stent during standard of care radiotherapy. ARM II: Patients receive standard of care during treatment.
Arms & interventions
- OtherBest Practice
Receive standard of care
- OtherMedical Device Usage and Evaluation
Wear 3D printed oral stent
Outcome measures
Primary
Mucositis toxicity rates
Rate of non-target mucose will be estimated along with the corresponding 95% confidence interval. Cochran-Mantel-Haenszel (CHM) test will be applied to compare mucositis rates between the two treatment arms. Logistic regression will be used to compare occurrence of mucositis between two arms, adjusting for the effects of stratification factors as well as other covariates. T test or Wilcoxon rank sum test will be used to compare three Olerud-Molander Ankle Score between two arms: a mean mucositis score, an extent of mucositis score, and a worst site score.
Time frame: Through study completion, an average of 1 year
Secondary
Patient reported outcomes
Time frame: Through study completion, an average of 1 year
Patients narcotics diaries
Time frame: Through study completion, an average of 1 year
Imaging difference
Time frame: Through study completion, an average of 1 year
Dosimetric difference
Time frame: Through study completion, an average of 1 year
Composite pain scores
Time frame: Through study completion, an average of 1 year
Number of narcotic pills used
Time frame: Through study completion, an average of 1 year
Eligibility criteria
Study locations (7)
Banner Health/Banner Research
Phoenix, Arizona, 85234
Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207
Community MD Anderson Cancer Center East
Indianapolis, Indiana, 46219
Community MD Anderson Cancer Center South
Indianapolis, Indiana, 46227
Community MD Anderson Cancer Center North
Indianapolis, Indiana, 46250
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
M D Anderson Cancer Center
Houston, Texas, 77030